Cluster Headache Dosing & Administration

Recommended dosing with no titration required1a

Image of three Emgality prefilled syringes

300 mg administered as 3 consecutive SC injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period.

  • 300 mg dose; this comes in 3 x 100 mg prefilled syringes
  • These 3 syringes are administered subcutaneously, one after another
  • Patients begin treatment at the onset of a cluster period
  • Patients take this 300 mg dose every month until their cluster period ends

Please review full Instructions for Use with your patients.

aThe Emgality prefilled syringe needle is 27 gauge x ½ inch.2

Consider having patients fill their prescription for their upcoming cluster cycle while they are in remission.

Advise patients to1,2:

  • Store product refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light until use
  • Check expiration date on product prior to use

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

How to administer Emgality

Preparation3

  • Inspect the prefilled syringe and the medicine. Do not use the prefilled syringe and dispose of it if it looks damaged; the expiration date printed on the label has passed; or the medicine is cloudy or discolored, has small particles, or is frozen
  • Choose an area for injection: abdomen or thigh if self-injecting, and buttocks or back of upper arm if another person is injecting. Be sure to choose a different site (even within an area) for each injection
  • Clean the site with an alcohol wipe and let it dry before injecting

3 key administration steps3

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

Hands removing cap from a syringe

1. Uncap the syringe

Abdomen skin pinched with needle inserted at 45 degree angle

2. Insert the needle at a 45° angle into a gently pinched fold of skin

Person injecting medicine into abdomen

3. Inject slowly until the gray syringe plunger is pushed to the needle end of the syringe

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Telephone receiver icon

Telephonic injection training and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

Watch how to use the Emgality prefilled syringe

Prescribing Information

Patient Information

Instructions for Use - 100 mg syringe for episodic cluster headache

If you or your patients have any questions about Emgality, call 1-833-EMGALITY (1-833-364-2548) to talk to a healthcare provider.

SC=subcutaneous.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

References

  1. Emgality. Prefilled Syringe Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0071.
  3. Emgality. Prefilled Syringe Instructions for Use. Lilly USA, LLC.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache